ClinicalTrials.gg
RecruitingNCT06216886Updated Jan 22, 2026

OnabotulinumtoxinA for Trigeminal Neuralgia

A Phase 4 interventional study of OnabotulinumtoxinA 100 UNT [Botox] and Sodium Chloride 0.9% for Injection, Preservative Free in Trigeminal Neuralgia, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Stanford University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.

Planned enrollment
16th of 26
20 · median 29
Started
2024
the only one that year
Phase 4
3 of 34
1 open now
Primary completion
2027-02
later than 4 of 10 live
Registered
33rd of 34
by date
Lead sponsor
4 of 34
Stanford University

Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one is the 16th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 4, reaches primary completion later than 4 of the 10 other live ones, and was the 33rd registered.

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

Browse Trigeminal Neuralgia studies →

Open to participants now

7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Trigeminal Neuralgia with a site in United States, or all of them as a file.
02

Study summary

A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.

Read the detailed description

This study will offer onabotulinumtoxin A (Botox) delivered intradermally into the region of pain for the patient with trigeminal neuralgia. Should they derive benefit from the procedure (as determined by decrease in the frequency of attacks), then they will be randomized to receive either onabotulinumtoxin A or saline and followed for 3 months. This study hopes to provide strong data that this is a treatment option for patients with TN who have failed medications, but are not ready for or do not want to undergo surgery.

03

Conditions studied

  • Trigeminal Neuralgia

Browse trials for

Keywords

  • botox
  • injection
  • trigeminal neuralgia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Men and women age 18 or older

  • Judged to be of legal competence
  • Sufficient knowledge of written and spoken English
  • Capable of attending regular in-person visits
  • Have failed/not a candidate/do not want surgery
  • Inadequate response to medication - at least 2 trials
  • Meeting ICHD criteria for Classical Trigeminal Neuralgia 13.1.1.1
  • Patients with frequency > 10 attacks per week
  • Stable dose of medications in the last 2 weeks

Exclusion criteria

Exclusion Criteria:

  • Secondary or Idiopathic TN, or Painful Trigeminal Neuropathy as defined by the ICHD (13.1.1.2, 13.1.1.3, 13.1.2)
  • Pregnant or breast feeding (while it is rare that a patient will be pregnant with TN, there is not sufficient data to say definitively that onabotA is ok to use during pregnancy and nursing, it is still rated Class C)
  • Neuromuscular disease
  • On aminoglyocosides
  • Not currently enrolled in any other studies
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    OnabotulinumtoxinA

    Intradermal injections will be placed in the affected trigeminal territories according to a specific facial map that we have developed.

    Drug: OnabotulinumtoxinA 100 UNT [Botox]

  • Placebo comparator
    Saline

    The same procedure will be followed as above, but saline will be injected instead of onabotA

    Drug: Sodium Chloride 0.9% for Injection, Preservative Free

Interventions

  • DrugBotulinum toxin type AStudies of Botulinum toxin type ABotulinum toxin type A pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.

    Also known as: Botox

  • DrugSodium Chloride 0.9% for Injection, Preservative Free

    intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Change in Number of TN Attacks per week

    Frequency of TN attacks before and after onabotA injection over a seven day period

    Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment))

Secondary outcomes

  1. Change in PROMIS Computer Adaptive Tests (PROMIS PROFILE CAT V1.0 -29)

    Computer adaptive tests (CATs) assess anxiety, depression, fatigue, pain interference, physical function, sleep disturbance and ability to participate in social roles and activities, and pain intensity.

    Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)

  2. Change in Severity of Attacks Based using the numerical rating scale (NRS)

    Average severity of attack over a 7 day period

    Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)

  3. Change In Baseline Pain Average using the numerical rating scale (NRS)

    baseline pain average over a seven day period

    Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)

  4. Change In Acute Medication Use

    Number of doses of any acute medication use over a 7 day period

    Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)

  5. Change In Patient Global Impression of Change

    A single self administered question given at week 4

    Time frame: week 4

07

Study locations

1 of 1 sites recruiting
  • Meredith Barad
    Stanford, California 94304, United States
    Recruiting
    • Meredith Study Team · Contactmbarad@stanford.edu · 650-721-7218
    • Meredith Barad, MD · Principal investigator
08

References and documents

Publications

  • undefined
  • Morra ME, Elgebaly A, Elmaraezy A, Khalil AM, Altibi AM, Vu TL, Mostafa MR, Huy NT, Hirayama K. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016 Dec;17(1):63. doi: 10.1186/s10194-016-0651-8. Epub 2016 Jul 5. PubMed 27377706 ↗
  • Wei J, Zhu X, Yang G, Shen J, Xie P, Zuo X, Xia L, Han Q, Zhao Y. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. Brain Behav. 2019 Oct;9(10):e01409. doi: 10.1002/brb3.1409. Epub 2019 Sep 21. PubMed 31541518 ↗
  • Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, Jin L. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain. 2013 Aug 21;14(1):72. doi: 10.1186/1129-2377-14-72. PubMed 23964790 ↗
  • Li S, Lian YJ, Chen Y, Zhang HF, Ma YQ, He CH, Wu CJ, Xie NC, Zheng YK, Zhang Y. Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. J Headache Pain. 2014 Jun 22;15(1):43. doi: 10.1186/1129-2377-15-43. PubMed 24952600 ↗
  • Zuniga C, Piedimonte F, Diaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol. 2013 Sep-Oct;36(5):146-50. doi: 10.1097/WNF.0b013e31829cb60e. PubMed 24045604 ↗
  • Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N, Wu C. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014 Sep 27;15(1):65. doi: 10.1186/1129-2377-15-65. PubMed 25263254 ↗
  • Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013 Nov 19;14(1):92. doi: 10.1186/1129-2377-14-92. PubMed 24251833 ↗
  • Tangney T, Heydari ES, Sheldon BL, Shetty A, Argoff CE, Khazen O, Pilitsis JG. Botulinum Toxin as an Effective Treatment for Trigeminal Neuralgia in Surgical Practices. Stereotact Funct Neurosurg. 2022;100(5-6):314-320. doi: 10.1159/000526053. Epub 2022 Aug 9. PubMed 35944492 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2024
First posted
Jan 22, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Feb 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06216886
Responsible party
Meredith Barad (Clinical Associate Professor of Anesthesiology (Pain) and Neurology & Neurological Sciences, Stanford University) — Principal investigator
First posted
Jan 22, 2024
Start date
Jun 1, 2024
Primary completion
Feb 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Jan 22, 2026

Study contacts

Meredith Barad, MD
Contact
nlariyos@stanford.edu
6507217218
Natali Ariyoshi
Contact
nlariyos@stanford.edu
6504978821
Meredith Barad, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion